Vanguard Capital Management
GALT icon

Vanguard Capital Management’s Galectin Therapeutics GALT Stock Holding History

Vanguard Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
2,168,065
+201,523
+10% +$522K ﹤0.01% 2812
2026
Q1 		$5.49M Buy
+1,966,542
New +$5.98M ﹤0.01% 3025

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management's GALT Position: Q2 2026 in Review

Vanguard Capital Management increased its Galectin Therapeutics (GALT) stake by 10% in Q2 2026, buying an estimated $522K and bringing the position to 2,168,065 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2812.

Vanguard Capital Management first reported a position in GALT in Q1 2026 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Vanguard Capital Management held 2,168,065 shares of Galectin Therapeutics worth $10.1M as of Q2 2026.
  • Vanguard Capital Management bought 201,523 Galectin Therapeutics shares in Q2 2026, an estimated $522K.
  • Galectin Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2812 holding.
  • Vanguard Capital Management first reported a position in Galectin Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.